DEF: TScan Therapeutics Seeks Stockholder Approval for Reverse Stock Split

TScan Therapeutics is holding a special meeting on November 20, 2026, to vote on a reverse stock split proposal aimed at regaining compliance with Nasdaq listing requirements.

Summary

• TScan Therapeutics is holding a Special Meeting of Stockholders on November 20, 2026, to vote on two proposals.
• Proposal 1: To approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the Company's common stock, with a ratio between 1-for-2 and 1-for-50, to be determined by the board of directors.
• Proposal 2: To approve an adjournment of the Special Meeting if necessary to solicit additional proxies for the Reverse Stock Split Proposal.
• The primary reason for the reverse stock split is to increase the per-share trading price of the Company's common stock to meet Nasdaq's minimum bid price requirement of $1.00 per share, as the stock was trading at $0.2379 on October 12, 2026.
• The Company received a deficiency letter from Nasdaq on August 27, 2026, and has until February 23, 2027, to regain compliance.
• The board of directors recommends voting FOR both proposals.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the company's precarious Nasdaq listing status and the necessity of a reverse stock split to avoid delisting, which often carries negative investor sentiment.

Positives

• The company is proactively addressing potential delisting from Nasdaq by seeking stockholder approval for a reverse stock split.
• The board of directors has the flexibility to set the reverse stock split ratio between 1-for-2 and 1-for-50, allowing for strategic implementation.
• The company is providing multiple options for stockholders to vote, including internet, telephone, and mail.

Negatives

• The company's common stock is trading significantly below Nasdaq's minimum bid price requirement ($0.2379 as of October 12, 2026, versus the $1.00 minimum).
• Failure to regain compliance with Nasdaq listing rules could lead to delisting, potentially moving the stock to less liquid over-the-counter markets.
• Reverse stock splits can carry a negative perception among investors and do not guarantee a sustained increase in stock price or market capitalization.
• The company may not be able to secure sufficient capital through future financing, potentially impacting its ability to continue as a going concern.

Risks

• The reverse stock split may not result in an increase in the per-share price of common stock or help the company regain compliance with Nasdaq listing requirements.
• The market price of common stock may decline after the reverse stock split, potentially at a greater percentage than before.
• The reverse stock split will increase the number of authorized but unissued shares, which could be used for future dilutive issuances.
• The company may not be able to secure sufficient additional capital through future financing, potentially impacting its ability to continue as a going concern.
• The company could face delisting from Nasdaq if it fails to meet the minimum bid price requirement within the specified compliance periods.

Future Outlook

The company is seeking approval for a reverse stock split to increase its per-share trading price and meet Nasdaq listing requirements. The board of directors has the discretion to implement the split within a specified range and timing, and may also abandon the split if deemed not in the best interest of the company and its stockholders. The company is also exploring various sources of financing, including potential future sales of common stock or other securities.

Management Comments

• The board of directors recommends voting FOR Proposal No. 1 (Reverse Stock Split) and FOR Proposal No. 2 (Adjournment Proposal).
• The board of directors believes that enabling the board to fix the specific ratio of the Reverse Stock Split within the stated range will provide flexibility to implement it in a manner designed to maximize the anticipated benefits for our stockholders.
• The board of directors strongly believes that the Reverse Stock Split is necessary to maintain our listing on Nasdaq.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common, albeit often viewed negatively, strategy for companies facing delisting due to low share prices. This is particularly prevalent in the biotechnology sector where stock price volatility can be high and funding rounds are critical.

Management Changes

Legal Proceedings

• The Company received a deficiency letter from The Nasdaq Stock Market LLC on August 27, 2026, regarding its failure to maintain the minimum closing bid price of $1.00 per share.

Stakeholder Impact

• Shareholders: Potential dilution from future stock issuances, possible negative perception of a reverse stock split, and risk of delisting impacting liquidity and investment value. However, a successful reverse split could improve investor interest and facilitate future financings.
• Employees: Potential impact on stock options and equity awards due to adjustments from the reverse stock split. Future hiring and retention may be influenced by stock price perception.
• Creditors: The company's ability to continue as a going concern is mentioned as a risk if financing is not secured, which could impact creditors.

Next Steps

• Stockholders to vote on the Reverse Stock Split Proposal and the Adjournment Proposal at the Special Meeting on November 20, 2026.
• If approved, the board of directors will determine the exact ratio and timing for the reverse stock split.
• The company must regain compliance with Nasdaq's minimum bid price rule by February 23, 2027.

Key Dates

Recommendation

The filing indicates a critical need to address Nasdaq listing requirements through a reverse stock split, which carries inherent risks and negative sentiment. While the company is taking action, the underlying business performance and ability to secure future financing remain key uncertainties. A 'hold' recommendation reflects a cautious approach, awaiting further developments on compliance and financial stability.

Keywords

Reverse Stock Split, Nasdaq Listing, Stockholder Meeting, Proxy Statement, Common Stock, Delisting Risk, Capital Raise